Recent Updates
Recently added Catalysts
RCEL Positive Sentiment

AVITA Medical Announces Participation at Canaccord Genuity Growth Conference

Key Takeaway: AVITA Medical, Inc. will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston from August 11-13, 2026. CEO Cary Vance is scheduled to speak on August 12 at 8:00 a.m. ET. Investors can request one-on-one meetings through Canaccord Genuity representatives. The company focuses on advanced wound care solutions, including the FDA-approved RECELL technology.

Market Sentiment Analysis

POSITIVE FACTORS

  • AVITA Medical is participating in a prominent conference.
  • The company is led by an experienced CEO, Cary Vance.
  • RECELL technology is recognized for its innovative wound care solutions.
  • The company has exclusive rights to market advanced wound care products.

Full Press Release Details

VALENCIA, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it will be participating at the Canaccord Genuity 46th Annual Growth Conference in Boston, taking place August 11–13, 2026.
AVITA Medical President and CEO Cary Vance will be speaking on Wednesday, August 12, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay will be available under the Investor Relations Events & Presentations section of AVITA Medical’s website, at: https://ir.avitamedical.com/events-and-presentations
Investors attending the conference may request a one-on-one meeting with AVITA Medical through their Canaccord Genuity sales representative.

About AVITA Medical, Inc.

AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx®, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix.
In international markets, RECELL is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds. RECELL and RECELL GO® are CE-marked in Europe, have TGA certification in Australia, and are listed with Medsafe in New Zealand; RECELL is PMDA-approved in Japan.
To learn more, visit www.avitamedical.com.

Investor & Media Contact: Ben Atkins Phone +1-805 341 1571 investor@avitamedical.com | media@avitamedical.com

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
©2026 AVITA Medical. AVITA Medical®, the AVITA Medical logo, Cohealyx®, RECELL®, RECELL GO®, and Spray-On Skin TM Cells are trademarks of AVITA Medical. PermeaDerm® is a registered trademark owned by Stedical Scientific, Inc. All other trademarks are the properties of their respective owners.

Frequently Asked Questions

When is AVITA Medical participating in the conference?

AVITA Medical will participate in the conference from August 11-13, 2026.

Who will represent AVITA Medical at the conference?

CEO Cary Vance will represent AVITA Medical and speak on August 12, 2026.

How can investors meet with AVITA Medical at the conference?

Investors can request one-on-one meetings through their Canaccord Genuity sales representative.

What is RECELL technology?

RECELL is an FDA-approved technology for treating thermal burn and trauma wounds.

Last updated: Aug 7, 2026